Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Coussens LM, Fingleton B, Matrisian LM (2002) Science 295: 2387-92 Matrix metalloproteinases: biologic activity and clinical implications. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM (2000) J Clin Oncol 18: 1135-49 MT2-MMP-dependent release of collagen IV NC1 domains regulates submandibular gland branching morphogenesis. Rebustini IT, Myers C, Lassiter KS, Surmak A, Szabova L, Holmbeck K, Pedchenko V, Hudson BG, Hoffman MP (2009) Dev Cell 17: 482-93 NMR-based screening in drug discovery. Hajduk PJ, Meadows RP, Fesik SW (1999) Q Rev Biophys 32: 211-40 Regression of glomerulosclerosis with high-dose angiotensin inhibition is linked to decreased plasminogen activator inhibitor-1. Ma LJ, Nakamura S, Aldigier JC, Rossini M, Yang H, Liang X, Nakamura I, Marcantoni C, Fogo AB (2005) J Am Soc Nephrol 16: 966-76 Unexpected effect of matrix metalloproteinase down-regulation on vascular intravasation and metastasis of human fibrosarcoma cells selected in vivo for high rates of dissemination. Deryugina EI, Zijlstra A, Partridge JJ, Kupriyanova TA, Madsen MA, Papagiannakopoulos T, Quigley JP (2005) Cancer Res 65: 10959-69 Cortactin is an essential regulator of matrix metalloproteinase secretion and extracellular matrix degradation in invadopodia. Clark ES, Whigham AS, Yarbrough WG, Weaver AM (2007) Cancer Res 67: 4227-35 Effect of ablation or inhibition of stromal matrix metalloproteinase-9 on lung metastasis in a breast cancer model is dependent on genetic background. Martin MD, Carter KJ, Jean-Philippe SR, Chang M, Mobashery S, Thiolloy S, Lynch CC, Matrisian LM, Fingleton B (2008) Cancer Res 68: 6251-9 Warm hepatic ischemia-reperfusion promotes growth of colorectal carcinoma micrometastases in mouse liver via matrix metalloproteinase-9 induction. Nicoud IB, Jones CM, Pierce JM, Earl TM, Matrisian LM, Chari RS, Gorden DL (2007) Cancer Res 67: 2720-8 Proteinase activity in human and murine saliva as a biomarker for proteinase inhibitor efficacy. Fingleton B, Menon R, Carter KJ, Overstreet PD, Hachey DL, Matrisian LM, McIntyre JO (2004) Clin Cancer Res 10: 7865-74 Phase I and pharmacokinetic study of prinomastat, a matrix metalloprotease inhibitor. Hande KR, Collier M, Paradiso L, Stuart-Smith J, Dixon M, Clendeninn N, Yeun G, Alberti D, Binger K, Wilding G (2004) Clin Cancer Res 10: 909-15 Uncoupling angiogenesis and inflammation in peripheral artery disease with therapeutic peptide-loaded microgels. Zachman AL, Wang X, Tucker-Schwartz JM, Fitzpatrick ST, Lee SH, Guelcher SA, Skala MC, Sung HJ (2014) Biomaterials 35: 9635-48 MMPs as therapeutic targets--still a viable option? Fingleton B (2008) Semin Cell Dev Biol 19: 61-8 NMR-based modification of matrix metalloproteinase inhibitors with improved bioavailability. Hajduk PJ, Shuker SB, Nettesheim DG, Craig R, Augeri DJ, Betebenner D, Albert DH, Guo Y, Meadows RP, Xu L, Michaelides M, Davidsen SK, Fesik SW (2002) J Med Chem 45: 5628-39 Functional selectivity of G protein signaling by agonist peptides and thrombin for the protease-activated receptor-1. McLaughlin JN, Shen L, Holinstat M, Brooks JD, Dibenedetto E, Hamm HE (2005) J Biol Chem 280: 25048-59 Synthesis and in vitro efficacy of MMP9-activated NanoDendrons. Samuelson LE, Scherer RL, Matrisian LM, McIntyre JO, Bornhop DJ (2013) Mol Pharm 10: 3164-74 Matrix metalloproteinase inhibitors for cancer therapy:the current situation and future prospects. Fingleton B (2003) Expert Opin Ther Targets 7: 385-97 Matrix metalloproteinase-9 inhibition improves proliferation and engraftment of myogenic cells in dystrophic muscle of mdx mice. Hindi SM, Shin J, Ogura Y, Li H, Kumar A (2013) PLoS One 8: e72121 CMT-3. CollaGenex. Fingleton B (2003) Curr Opin Investig Drugs 4: 1460-7 Pharmacologic and genetic manipulation of MMP-2 and -9 affects retinal neovascularization in rodent models of OIR. Barnett JM, McCollum GW, Fowler JA, Duan JJ, Kay JD, Liu RQ, Bingaman DP, Penn JS (2007) Invest Ophthalmol Vis Sci 48: 907-15 Matrix metalloproteinases as valid clinical targets. Fingleton B (2007) Curr Pharm Des 13: 333-46 Intraarterial administration of norcantharidin attenuates ischemic stroke damage in rodents when given at the time of reperfusion: novel uses of endovascular capabilities. Khan IS, Odom M, Ehtesham M, Colvin D, Quarles CC, McLaughlin B, Singer RJ (2016) J Neurosurg 125: 152-9 Molecular imaging of proteolytic activity in cancer. McIntyre JO, Matrisian LM (2003) J Cell Biochem 90: 1087-97 A matrix metalloproteinase inhibitor promotes granuloma formation during the early phase of Mycobacterium tuberculosis pulmonary infection. Izzo AA, Izzo LS, Kasimos J, Majka S (2004) Tuberculosis (Edinb) 84: 387-96
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.